Evidence map›Paper›PMID 40274989›Full record

ArticleCommunications biology2025

Induction of cardiac fibulin-4 protects against pressure overload-induced cardiac hypertrophy and heart failure.

E D van Deel, M Snelders, N van Vliet, L Te Riet, T P P van den Bosch, L R Fiedler, A C C van Spreeuwel, N A M Bax, N Boontje, C M Halabi and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

E D van Deel *Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
M Snelders *Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0002-6306-9270
N van VlietDepartment of Molecular Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
L Te RietDivision of Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
T P P van den BoschDepartment of Pathology and Clinical Bioinformatics, Erasmus University Medical Center, Rotterdam, the Netherlands.
L R FiedlerBritish Heart Foundation Centre of Research Excellence, National Heart and Lung Institute, Imperial College London, London, UK.
A C C van SpreeuwelDepartment of Biomedical Engineering, and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.
N A M BaxDepartment of Biomedical Engineering, and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.
N BoontjeDepartment of Physiology, VU University Medical Center, Institute for Cardiovascular Research (ICaR-VU), Amsterdam, the Netherlands.
C M HalabiDivision of Nephrology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-4889-8131
T SasakiDepartment of Pharmacology, Faculty of Medicine, Oita University, Oita, Japan.ORCID http://orcid.org/0000-0003-0514-9931
D P ReinhardtFaculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-6535-9872
J van der VeldenDepartment of Physiology, VU University Medical Center, Institute for Cardiovascular Research (ICaR-VU), Amsterdam, the Netherlands.
C V C BoutenDepartment of Biomedical Engineering, and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0003-1035-5094
J H von der ThüsenDepartment of Pathology and Clinical Bioinformatics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0001-9699-4860
A H J DanserDivision of Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0002-5052-3585
D J DunckerDivision of Experimental Cardiology, Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0003-2836-2241
M D SchneiderBritish Heart Foundation Centre of Research Excellence, National Heart and Lung Institute, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-9645-1938
I van der PluijmDepartment of Molecular Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0002-9368-5779
J EssersDepartment of Molecular Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands. j.essers@erasmusmc.nl.ORCID http://orcid.org/0000-0003-0605-7211

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevailing view of fibulin-4 deficient mice is that the cardiac phenotype is the result of aortic and/or valvular disease. In the present study, we have tested whether the cardiac phenotype is, at least in part, the consequence of primary cardiac effects of fibulin-4. We have found fibulin-4 expression to be activated throughout the myocardium in wildtype (fibulin-4

Indexed as

CardiomegalyExtracellular Matrix ProteinsHeart FailureMyocardiumAnimalsMaleMiceMice, Inbred C57BLMyocytes, CardiacExtracellular Matrix Proteins

Identifiers

PMID40274989
PMCPMC12022050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.